Detalhe da pesquisa
1.
TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers.
Nature
; 628(8007): 416-423, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538786
2.
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia.
Blood
; 141(25): 3031-3038, 2023 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37084383
3.
Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
Blood
; 139(13): 1999-2010, 2022 03 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-34780623
4.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024.
J Natl Compr Canc Netw
; 22(3): 175-204, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38626800
5.
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
Am J Hematol
; 98(2): 300-308, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588409
6.
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Lancet Oncol
; 23(8): 1066-1077, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35839786
7.
Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel.
Br J Haematol
; 199(5): 720-727, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36111395
8.
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.
Blood
; 135(25): 2224-2234, 2020 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32232481
9.
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
J Natl Compr Canc Netw
; 20(6): 622-634, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35714675
10.
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol
; 22(10): 1403-1415, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34516954
11.
Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Support Care Cancer
; 29(2): 833-840, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32500206
12.
Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study.
Biol Blood Marrow Transplant
; 26(9): 1679-1688, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32592857
13.
Assessing Early Supportive Care Needs among Son or Daughter Haploidentical Transplantation Donors.
Biol Blood Marrow Transplant
; 26(11): 2121-2126, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32781288
14.
Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia.
Biol Blood Marrow Transplant
; 26(3): 502-508, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31730920
15.
Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Biol Blood Marrow Transplant
; 26(12): 2306-2310, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32961372
16.
A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma.
Biol Blood Marrow Transplant
; 26(12): 2223-2228, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32829079
17.
Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide.
Biol Blood Marrow Transplant
; 26(11): 2075-2081, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32818556
18.
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Cancer
; 126(2): 293-303, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31568564
19.
Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy.
Br J Haematol
; 189(2): 313-317, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31804715
20.
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy.
Br J Haematol
; 191(1): 44-51, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32430944